Clinical trial · Interventional
Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
A Prospective, Single-arm Phase II Study of Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
NCT06730308CI-TRIAL-00083672recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thymoma | Thymoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Concurrent chemotherapy | Drug | — | UNRESOLVED |
| Methylprednisolone | Drug | — | UNRESOLVED |
| Radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Study arm
- description
- Methylprednisolone combined with concurrent chemoradiotherapy
- interventionNames
- Radiation: Radiotherapy
- Drug: Concurrent chemotherapy
- Drug: Methylprednisolone
Primary outcomes (1)
- measure
- Objective response rate
- timeFrame
- 1-2 months after chemoradiotherapy
- description
- The percentage of patients who achieve complete remission or partial remission after chemoradiotherapy
Secondary outcomes (4)
- measure
- Progression-free survival
- timeFrame
- 2-year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed type AB or B1-3 thymoma. * Measurable Disease: Patients must have measurable disease as defined by RECIST (Response Evaluation Criteria in Solid Tumors). * Unresectable or recurrent thymoma, with the tumor confined to the chest and neck area. * Between the ages of 18 and 70 years, regardless of sex. * Eastern Cooperative Oncology Group performance status of 0 or 1. * No prior chest radiation. * Adequate organ Functions. * Written informed consent obtained. Exclusion Criteria: * Contraindications to Methylprednisolone. * History of or Concurrent Malignancy. * Active infection, myocardial infarction within the last 6 months or symptomatic heart disease. * Pregnant or Lactating Women. * Bleeding Disorders. * Recent Participation in Other Clinical Trials. * Drug Abuse or Severe Alcoholism. * Uncontrolled Seizures or Mental Disorders. * Severe Allergies or Specific Sensitivities.
References
Publications (0)
Data not yet available
No reference posted for this study.